Abstract
CKD is a common disease that is estimated to develop one in eight persons in Japan. The CKD itself is highly risk factor on the cardiac/vascular mortality. In addition,a new concept has been proposed "CKD-MBD". CKD-MBD is composed of a combination of abnormal mineral metabolism, abnormal bone, and extra skeletal calcification with cardiovascular high mortality. Treatment for CKD-MBD is a wide-ranging. We aim to decline cardiovascular event, fracture, and mortality rate of patients with CKD. The main therapeutic target for CKD-MBD becomes the phosphate control. Today, we can use of the VRDA, Calcimimetics and muti-phosphate binders as a lot of pharmacological intervention.
MeSH terms
-
Bone Diseases, Metabolic / diagnosis
-
Bone Diseases, Metabolic / etiology*
-
Bone Diseases, Metabolic / metabolism
-
Bone Diseases, Metabolic / therapy*
-
Bone and Bones / metabolism*
-
Bone and Bones / pathology
-
Calcimimetic Agents / therapeutic use
-
Calcinosis
-
Calcium Carbonate / therapeutic use
-
Cardiovascular Diseases / etiology
-
Cinacalcet / therapeutic use
-
Ferric Compounds / therapeutic use
-
Fractures, Bone / etiology
-
Humans
-
Minerals / metabolism*
-
Parathyroidectomy
-
Phosphates / metabolism
-
Phosphorus, Dietary / administration & dosage
-
Renal Insufficiency, Chronic / complications*
-
Risk Factors
-
Sevelamer / therapeutic use
Substances
-
Calcimimetic Agents
-
Ferric Compounds
-
Minerals
-
Phosphates
-
Phosphorus, Dietary
-
ferric citrate
-
Sevelamer
-
Calcium Carbonate
-
Cinacalcet